

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Altairano, Inc.		08/04/2009	CORPORATION: NEVADA
RECEIVING PARTY DATA			
Name:	Spectrum Pharmaceuticals, Inc.		
Street Address:	157 Technology Drive		
City:	Irvine		
State/Country:	CALIFORNIA		
Postal Code:	92618		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 1			
Property Type	Number	Word Mark	
Registration Number:	2922141	RENAZORB	
CORRESPONDENCE DATA			
Fax Number:	(908)654-7866		
	<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>		
Phone:	908-654-5000		
Email:	trademarkadmin@ldlkm.com		
Correspondent Name:	LERNER, DAVID, LITTENBERG, ET AL		
Address Line 1:	600 SOUTH AVENUE WEST		
Address Line 4:	WESTFIELD, NEW JERSEY 07090		
ATTORNEY DOCKET NUMBER:	SPHARM 10.1-007		
NAME OF SUBMITTER:	KEIR J. LOIACONO		
Signature:	/KEIR J. LOIACONO/		
Date:	09/28/2010		

CH \$40.00 2922141

Total Attachments: 2

source=SPHARM 10.1-007 Assignment DO NOT DELETE#page1.tif

source=SPHARM 10.1-007 Assignment DO NOT DELETE#page2.tif

CONFIRMATORY ASSIGNMENT

Docket Number (Optional)

PTO/SB/15 (8-00) Modified by LDLK&M

WHEREAS, **Altairnano, Inc. ("Assignor")**, a corporation of the State of **Nevada**, located and doing business at **204 Edison Way, Reno, Nevada 89502** was the sole and exclusive owner of the United States trademarks listed in Schedule A:

SEE SCHEDULE "A" ATTACHED HERETO.

WHEREAS, **Spectrum Pharmaceuticals, Inc. ("Assignee")**, a corporation of **Delaware**, located and doing business at **157 Technology Drive, Irvine, California 92618** has acquired the right, title and interest in, to and under the trademarks listed in Schedule "A" ("Subject Trademarks"); including the trademark registration therefor, together with the goodwill of the business symbolized by the Subject Trademarks, and all common law rights associated with the use of the Subject Trademarks in the United States of America and all other countries;

WHEREAS, this assignment confirms that Assignee acquired such rights in such Subject Trademarks under an agreement dated August 4, 2009 ("The Agreement"), for good and valuable consideration and in accordance with The Agreement, **Assignor** thereby transferred, assigned, conveyed, delivered and vested to **Assignee**, all of **Assignor's** interests and rights in the Subject Trademarks in all countries, jurisdictions and political entities of the world; and

NOW, THEREFORE, in consideration of The Agreement and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending to be legally bound, agree as follows:

1. Assignment.

Under The Agreement, **Assignor**, assigned, conveyed, transferred, delivered, and agreed to assign, convey, transfer and deliver to **Assignee**, its successors, assigns and legal representatives or nominees, **Assignor's** entire right, title and interest in and to the Subject Trademarks for all countries, jurisdictions and political entities of the world, along with the right to sue for past infringement (including all current and future claims and causes of action), with respect to which, and to the extent to which, **Assignor** had or hereafter acquires the right to so assign, convey, transfer and deliver.

IN WITNESS WHEREOF, **Altairnano, Inc.**, has caused these presents to be signed by its duly appointed trustee having full authority to sign on its behalf.


7-28-10
(Date)

John Fallini
(Signature)

State of Nevada) SS:
County of Washoe)

On this 28 day of July, 2010 before me appeared John Fallini, the person who signed this instrument, who acknowledged that he signed it as a free act on behalf of **Altairnano, Inc.** with authority to do so.

Sheri Stanoff
(Notary Public)



SCHEDULE A

AGENT'S FILE NAME	COUNTRY	REGISTRATION NUMBER	MARK	TITLE
SPHARM 10.1-007	US	2922141	RENAZORB	Pharmaceutical compositions containing lanthanum used to decrease the serum phosphate level in humans and other mammals with phosphatemia.
		NA/Common Law Mark	RENALAN	